Replies to post #358749 on Innovation Pharmaceuticals Inc (IPIX)

[Lemoncat]

My guess is Ivermectin does not fall into one of the two categories int the article while the others do/did:

1.COVID-19 treatments that have received EMA advice
2.Ongoing clinical trials in the EU

I'm not really interested enough to go search though. Brilacidin is not included because, to my knowledge, we have had no interaction with EMA on B-COVID and are not running a trial site in the EU.

Go IPIX!

[sunspotter]

More on ivermectin, which still looks promising:

"Conclusions:
Moderate-certainty evidence finds that large reductions in COVID-19 deaths are possible using ivermectin. Using ivermectin early in the clinical course may reduce numbers progressing to severe disease. The apparent safety and low cost suggest that ivermectin is likely to have a significant impact on the SARS-CoV-2 pandemic globally."


https://journals.lww.com/americantherapeutics/Abstract/9000/Ivermectin_for_Prevention_and_Treatment_of.98040.aspx